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Abstract 
Gut microbiota and their metabolites are instrumental in regulating homeostasis at intestinal and 
extra-intestinal sites. However, the complex effects of prenatal and early postnatal microbial 
exposure on adult health and disease outcomes remain incompletely understood. Here, we 
showed that mice raised under germ-free conditions until weaning and then transferred to 
specific-pathogen free conditions, harbored altered microbiota composition, augmented 
inflammatory cytokine and chemokine expression, and were hyper-susceptible to colitis-
associated tumorigenesis later in adulthood. Increased number and size of colon tumors and 
intestinal epithelial cell proliferation in recolonized germ-free mice were associated with 
augmented intratumoral CXCL1, CXCL2, CXCL5 expression and granulocytic myeloid-derived 
suppressor cell accumulation. Consistent with these findings, CXCR2 neutralization in 
recolonized germ-free mice completely reversed the exacerbated susceptibility to colitis-
associated tumorigenesis. Collectively, our findings highlight a crucial role for early-life 
microbial exposure in establishing intestinal homeostasis that restrains colon cancer in 
adulthood.  
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Introduction 
The gut microbiota consists of trillions of bacteria that co-develop with the host and foster 
physiological and immunological homeostasis (1-3). Microbiota-induced immune responses are 
particularly important early in life (4,5) when the maternal microbiota can influence prenatal and 
early post-natal host development (6). Exposure to microbiota and associated metabolites during 
this time may have long-lasting effects on immune and non-immune homeostasis of the gut and 
other organs, and ultimately disease outcomes. Because colitis-associated cancer (CAC) is 
influenced by the microbiota and inflammatory signaling pathways (7), we explored the 
contribution of early-life microbiota exposure to the development of CAC later in life.  
Here, we show that mice raised under germ-free conditions until weaning and then 
conventionalized with complex gut microbiota into adulthood (exGF mice) were hyper-
susceptible to CAC when compared to specific pathogen-free (SPF) mice. The increased number 
and size of colon tumors and intestinal epithelial cell (IEC) proliferation in exGF mice were 
associated with augmented intratumoral chemokine expression and granulocytic myeloid-derived 
suppressor cell (G-MDSC) accumulation. Accordingly, CXCR2 neutralization in exGF mice 
reversed the hyper-susceptibility to CAC. Collectively, these findings highlight a crucial role for 
early-life microbiota in establishing gut homeostasis that restrains colon cancer in adulthood.  
 
Methods 
Mice 
C57BL/6 mice were obtained from the Jackson Laboratories and housed in SPF conditions (SPF 
mice). GF C57BL/6 mice were kept under GF conditions in Park Bioservices isolators. 
Conventionalization of GF mice was performed after weaning at the age of 3 weeks (21 days) by 
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transferring the GF mice out of GF isolators and co-housing them with SPF mice for 3 weeks 
(exGF mice). Animal protocols were approved by the IACUC of Georgia State University.  
 
Colitis-associated cancer model 
CAC was induced as previously described (8). Briefly, as shown in Fig. 1A, SPF and exGF mice 
were intraperitoneally injected with AOM (10 mg/kg body weight) (Sigma) diluted in PBS. Mice 
were then subjected to two cycles of dextran sodium sulfate (DSS) treatment (MP Biomedicals), 
in which each cycle consisted of 2.5% DSS for 7 days followed by 14 days with regular water. 
After the colitis-associated cancer protocol was complete (day 122 of life; day 80 following 
initiation of the AOM/DSS regimen), mice were euthanized, and colon length, colon weight, and 
spleen weights were measured. At day 98 and 122 of life, mice were fasted for 15 hours, and the 
colonoscopy procedure was performed under general anesthesia with isoflurane (Karl Storz 
Endoskope, El Segundo, CA). 
 
CXCR2 neutralization in vivo 
Mice were injected with anti-CXCR2 (polyclonal goat anti-mouse; a gift from Dr. Lukacs) or 
goat IgG (isotype control; Bio X Cell) via the intraperitoneal route (500 g twice a week) 
beginning 4 days after the AOM injection. Antibodies against CXCR2 were generated by 
immunization of a goat with murine CXCR2 peptide in multiple intradermal sites and purified 
over a protein A column as previously described (9).  
 
Isolation of colonic lamina propria (LP) cells and flow cytometry 
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Isolation of colonic LP cells was performed as previously described (10). Briefly, colonic tissue 
was cut into pieces 0.5 cm in length and placed in an orbital shaker for 20 minutes at 37°C in 
Hank’s Balanced Salt Solution (HBSS) with 10% fetal bovine serum (FBS) and 2 mM EDTA in 
order to remove epithelial cells. This shaking step was repeated and then the remaining tissue 
was minced and placed in RPMI with 10% FBS, collagenase IV (1 mg/mL; Sigma), and DNase I 
(40 U/mL; Roche) and shaken for 15 minutes at 37°C. The contents are then filtered through a 
100 μm cell strainer directly into a 50-mL conical tube. Each 50-mL conical tube was topped off 
with HBSS with FBS and centrifuged at 4 °C twice. The cell pellet was resuspended into a cell 
suspension, which was stained with specific antibodies and analyzed by flow cytometry. 
Fluorescence-labeled antibodies were from Thermo Fisher Scientific: CD11b (M1/70), CD11c 
(N418), CD127 (A7R43), F4/80 (BM8), CD90.2 (53-2.1), Ly6C (HK1.4), Ly6G (1A8), Ki67 
(16A8); from Becton Dickinson (BD):  MHC-II (M5/114.15.2), CD3 (145-2C11), CD4 (L3T4), 
CD8 (5H10), CD45 (30F11), E-cadherin (DECMA-1); Biolegend: NK1.1 (PK136), TCR 
(H57-597). Fc block (2.4G2) was purchased from BD. LIVE/DEAD fixable aqua dead cell stain 
(Thermo Scientific) was used as a viability dye.  
 
16S rRNA and mRNA sequencing  
Ilumina 16S ribosomal (r)RNA gene sequencing was performed on feces isolated from SPF and 
exGF mice at days 42, 98, and 122, as previously described (11). Briefly, quality filtering was 
performed using the Quantitative Insights Into Microbial Ecology (QIIME; http://qiime.org) 
software package (12), and sequences were aligned to operational taxonomic units (OTUs) using 
the UCLUST algorithm (13) and classified taxonomically using the Greengenes reference 
database 13_8 (14). A single representative sequence for each OTU was aligned, and a 
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phylogenetic tree was built using FastTree (15). The phylogenetic tree was used for computing 
the unweighted UniFrac distances between samples, rarefaction was performed, and used to 
compare abundances of OTUs across samples. Rarefaction was performed at 12962 sequences 
per sample, for which a total of 5650 OTUs were observed (818 +/- 203 per sample). Principal 
coordinates analysis (PCoA) plots were generated through QIIME and used to assess the 
variation between experimental groups (beta diversity). The PCoA plot representations are 3D 
and the dot sizes are dependent on the relative localization. Alpha diversity was analyzed using 
the Shannon index. LEfSe (LDA Effect Size) was used to investigate bacterial members that 
drive differences between groups, with a significance level of 2 used as a threshold (16). The 
mRNA-seq experiments were performed by Novogene (Beijing, China). Volcano plots were 
generated using R, and heatmaps were generated using Morpheus 
(https://software.broadinstitute.org/morpheus/). Pie chart representation of pathways was 
performed using Panther Classification System (http://pantherdb.org) to gain insight into specific 
signaling pathways. The accession numbers for the unprocessed transcriptomic sequencing data 
and the unprocessed 16S sequencing data reported in this paper are in the European Nucleotide 
Archive: PRJEB30607 and PRJEB30606, respectively.  
 
Histology  
Mouse distal colons with tumors were fixed in 10%-buffered formalin for 24 hours at room 
temperature and subsequently embedded in paraffin. Sectioning, hematoxylin/eosin staining, 
slide scanning, and assessment of histology were subsequently performed at the Institute for 
Biomedical Sciences histology core at Georgia State University by using a BX61 microscope 
(OLYMPUS).  
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TUNEL assay 
To quantitate the number of apoptotic cells in colonic epithelial cells, mouse proximal colon 
devoid of tumor were fixed in 10%-buffered formalin for 24 hours at room temperature, 
embedded in paraffin, sectioned at 5-μm thickness, deparaffinized, and stained for apoptotic 
nuclei according to the manufacturer’s instructions using the In-Situ Cell Death Detection Kit 
(Sigma Aldrich, St. Louis, MO). TUNEL-positive cells overlapping with DAPI nuclear staining 
were counted per crypt by using a BZ-X710 microscope (Keyence). 
 
RNA isolation and qPCR 
Total RNA was isolated from murine colonic tissues using the Qiagen RNeasy Mini Kit and 
QIAcube with on-column DNase digestion. The RNA concentration was measured using 
NanoDrop 8000 (Thermo Scientific). cDNA was generated from 1g of RNA using the 
Superscript First-Strand Synthesis System for RT-PCR and random hexamer primers 
(Invitrogen). qPCR was performed with SYBR Green on a StepOnePlus real-time PCR system 
(Applied Biosystems). Gene expression was normalized to Gapdh and analyzed using 2
–ΔΔCT
 
method with duplicates. 
Primers used were:  
cxcl1 (F: GCTTGAAGGTGTTGCCCTCAG; R: AAGCCTCGCGACCATTCTTG) 
cxcl2 (F: CGCTGTCAATGCCTGAAG; R: GGCGTCACACTCAAGCTCT) 
cxcl5 (F: GGTCCACAGTGCCCTACG; R: GCGAGTGCATTCCGCTTA) 
gapdh (F: TGGCAAAGTGGAGATTGTTGCC; R: AAGATGGTGATGGGCTTCCCG) 
 
on February 21, 2019. © 2019 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 19, 2019; DOI: 10.1158/2326-6066.CIR-18-0444 
8 
Human microarray analysis 
Microarray datasets (GSE37283; (17)) were downloaded from the Gene Expression Omnibus 
database (ttps://www.ncbi.nlm.nih.gov/geo/). Detailed patient demographic information is 
available in Table 1 of (17).  Microarray analysis was performed as previously described (18). 
Microarray assay were performed on 20 RNA samples isolated from colon mucosa of 20 
patients, including 5 normal controls, 4 quiescent UC, and 11 UC with neoplasia. Inclusion 
criteria is as follows: a previous clinical diagnosis of UC confirmed by an expert GI pathologist, 
a disease duration > 7 years, and an extent of disease >20 cm proximal to the anal verge. For 
microarray analysis, expression and raw expression data were summarized and normalized using 
the Robust Multi-array Average algorithm from the Bioconductor library for the R statistical 
programming system. All samples were clustered using Ward's method in Spotfire (TIBCO 
Software, Palo Alto, CA). 
 
Statistics 
Statistical analyses were performed with GraphPad Prism software, version 6.0b (Graphpad 
Software). Student’s t test or one-way ANOVA and Tukey’s Multiple Comparison Test was used 
to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant.  
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Results 
 
Absence of microbiota prior to weaning exacerbates colitis-associated cancer in adult mice 
To investigate the contribution of early-life microbiota exposure to CAC, we compared SPF 
mice to exGF mice (born and raised in GF conditions until weaning at day 21 when they were 
co-housed with age- and sex-matched SPF mice for an additional 21 days). Both groups of mice 
were subsequently administered AOM at day 42 of life followed by two 7-day cycles of DSS to 
induce CAC (Fig. 1A). We observed that exGF mice lost significantly more body weight 
compared to SPF mice, beginning during the first cycle of DSS (Fig. 1B). ExGF mice also 
developed significantly larger colonic tumors, as assessed by endoscopy at day 98 and 122 (Fig. 
1C) and macroscopic examination (Fig. 1D). Similar differences between exGF and SPF mice 
were observed for total tumor surface area (Fig. 1E), tumor surface area per individual tumor at 
day 122 (Fig. 1F), and in the total number of colonic tumors, specifically in the 1-2mm and 2-
3mm size range (Fig. 1G). We did not observe significant differences in spleen weights and 
colon lengths between the groups (Fig. 1H). These data demonstrated that the lack of microbiota 
before weaning favors CAC development in adulthood.   
 
Enhanced colonic tumor size and epithelial turnover in AOM/DSS-treated exGF mice 
Histological examination confirmed the presence of larger adenomas particularly in the middle to 
distal colonic region and rectum in AOM/DSS-treated exGF mice compared to SPF controls 
(Supplementary Fig. S1A-B). Given this increased tumor burden observed in the exGF group, we 
investigated whether colonic epithelial cell death and proliferation were altered in these mice. 
We observed a significantly increased number of TUNEL
+
 cells in tissue sections 
(Supplementary Fig. S1C-D), and increased Ki67 staining of isolated intestinal epithelial cells 
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(IECs) (Supplementary Fig. S1E-F) among exGF mice compared to SPF controls. These results 
suggest that increased IEC turnover in exGF mice may enhance CAC. 
 
ExGF mice exhibit altered microbiota composition and colonic gene expression 
We next analyzed the microbiota and host gene expression that may be associated with and/or 
contribute to the enhanced colonic tumor burden in exGF mice. To analyze microbiota 
composition, 16S rRNA gene sequencing was performed on feces isolated from SPF and exGF 
mice at days 42, 98, and 122. Principal coordinate analysis (PCoA) of the unweighted Unifrac 
distance revealed separate clustering of SPF (blue dots) and exGF samples (red dots) at day 42 
preceding initiation of AOM/DSS (Fig. 2A). We observed distinct clustering between SPF and 
exGF mice (blue and red dots, respectively; Supplementary Fig. S2A) at day 42 (red dots; 
Supplementary Fig. S2B), with this microbiota clustering becoming more distinct at day 98 and 
day 122 (blue and orange dots, respectively; Supplementary Fig. S2B).  We observed two 
subgroups for both SPF and exGF animals at day 42 (Fig. 2A), which could be explained by the 
samples originating from two independent experiments. Shannon index analysis demonstrated 
that the alpha diversity of exGF mice was not significantly altered compared to SPF mice 
(Supplementary Fig. S2C). We next analyzed the unweighted Unifrac distance separating these 
groups in order to quantitate the differences, which confirmed that alterations in the microbiota 
composition between SPF and exGF mice was present at day 42 and significantly exacerbated at 
day 98 and 122 (Fig. 2B). Microbiota alteration in exGF mice at day 42 was characterized by 
increases in members of the families Verrucomicrobiaceae, Rikenellaceae, and 
Erysipelotrichaceae and reductions in Dehalobacteriaceae, Peptococcaceae, and 
Ruminococcaceae (Fig. 2C, Supplementary Fig. S2D-E).  
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We next performed RNA-seq analysis of total colon tissue at days 7, 14, 21, and 42 of 
life, all prior to the initiation of AOM-DSS. Volcano plots indicated that the number of genes 
significantly upregulated or downregulated in exGF mice by at least 2-fold at day 14 (96 genes 
up in exGF; 253 genes down in exGF) and day 21 (375 genes up in exGF; 216 genes down in 
exGF) were higher than at day 7 (96 genes up in exGF; 82 genes down in exGF) and day 42 (97 
genes up in exGF; 100 genes down in exGF) (Fig. 2D, Supplementary Fig. S3A). These data are 
consistent with the expansion of microbiota in SPF mice, but not GF mice, around the time of 
transitioning away from breast milk to eating solid food (~day 14) and the time of weaning (day 
21). At day 42, just prior to the initiation of AOM/DSS, analysis of specific genes that were 
significantly upregulated in exGF mice revealed higher expression of the monocyte chemokine 
Ccl8, the antimicrobial peptide Reg3g and several pro-proliferative genes (Mmp3, Wnt2, 
HOXD3, Kif26b). Alternatively, lower expression of anti-inflammatory genes (Il2, Unc5c) and 
tumor suppressor genes (Nod2, Lgi3, Klf12) were observed in exGF mice (Fig. 2D).  
We further performed heatmap analyses of SPF and exGF colon tissue samples from day 
42 and found that 551 genes were differentially expressed (Supplementary Fig. S3B). Pie chart 
representation of pathways was used to gain insight into specific signaling pathways that may 
have been altered by early-life microbiota by analyzing genes with a more than 2-fold increase 
expression in exGF mice compared to SPF mice. This approach identified the ‘inflammation-
mediated by chemokine and cytokine signaling pathway’ as one of the most enriched pathways 
(Supplementary Fig. S3C). Collectively, these data indicated a steady-state shift towards a pro-
proliferative, pro-inflammatory milieu in the colons of exGF mice, which is associated with 
distinct microbiota composition and enhanced CAC. 
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Enhanced CXCR2 ligands and granulocytic MDSCs in AOM/DSS-treated exGF mice  
In light of enhanced pro-inflammatory gene expression and the alteration in the expression of 
cytokine/chemokine signaling pathways in exGF mice at day 42, we next explored how specific 
chemokine signaling may contribute to increased CAC. We focused on the CXCL2/CXCR2 axis 
because CXCR2-dependent recruitment of myeloid-derived suppressor cells (MDSCs) has been 
implicated in CAC (19). Using qRT-PCR we observed higher CXCL1 and CXCL2 mRNA 
expression in tumor tissues (T), but not non-tumor tissue (N), obtained from exGF mice 
compared to SPF mice, and CXCL5 mRNA followed a similar trend (Fig. 3A). To examine 
whether increased CXCR2 ligand expression was associated with enhanced MDSCs, we next 
analyzed granulocytic MDSCs (G-MDSCs; CD11b
+
Ly6G
high
) and monocytic MDSCs (M-
MDSCs; CD11b
+
Ly6C
+
) (20) in colons from AOM/DSS-treated exGF and SPF mice. Following 
treatment with AOM/DSS, FACS analyses of colonic tissues revealed that exGF
 
mice displayed 
significantly increased accumulation of G-MDSCs, but not M-MDSCs, compared to SPF mice 
(Fig. 3B-E).  
We next investigated whether CXCR2 ligands were also enhanced during CAC in 
humans using datasets for colonic tissues obtained from healthy controls (HC) and ulcerative 
colitis (UC) patients with or without remote colonic neoplasia. In UC patients, the expression of 
the CXCR2, as well as the CXCR2 ligands CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8, 
were all elevated in colonic tissue isolated from patients harboring remote colonic neoplasia 
compared those without remote neoplasia or HC (Supplementary Fig. S4). Taken together, these 
data suggest that a lack of microbiota in early-life may enhance expression of CXCR2 ligands 
accumulation of G-MDSCs in colonic tissue. 
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CXCR2 blockade inhibits colonic tumorigenesis in AOM/DSS-treated exGF mice 
We further explored whether in vivo neutralization of CXCR2 could limit the enhanced 
recruitment of MDSCs, as well as CAC observed in these mice. Indeed, anti-CXCR2 treatment 
inhibited the development of AOM/DSS-induced macroscopic colonic tumors in exGF mice to a 
similar extent as that observed in anti-CXCR2-treated SPF mice, when compared to either group 
treated with control IgG (Fig. 4A). Similar effects of anti-CXCR2 treatment were observed with 
regards to inhibiting total tumor surface area (Fig. 4B), tumor surface area per individual tumor 
at day 122 (Fig. 4C), and the total number of colonic tumors (Fig. 4D), whereas no significant 
differences in spleen weights and colon lengths between the two groups were seen (Fig. 4E). We 
confirmed that injection of anti-CXCR2 into AOM/DSS-treated SPF and exGF mice prevented 
G-MDSC accumulation in colonic tissue (Fig. 4F). 
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Discussion 
A previous report demonstrated that AOM/DSS-treated GF mice develop more CAC compared 
to SPF mice and linked this phenotype to impaired inflammatory responses and delayed repair 
processes (21). Our complementary findings show that exGF mice had an altered microbiota, 
enhanced chemokine expression and G-MDSCs in the colon, and were hyper-susceptible to 
CAC. These data indicate that early-life exposure to microbiota induced enduring microbial and 
host changes that predisposed mice to CAC.  
The microbiota differences in exGF mice were characterized by increases in 
Verrucomicrobiaceae, Rikenellaceae, and Erysipelotrichaceae.  These results are consistent with 
reports that Akkermansia, Bacteroidales, and Erysipelotrichaceae correlate with increased CAC 
(22,23). Both Bacteroides and Akkermansia are mucin degraders, and an overabundance of these 
bacteria may impair mucosal barrier defenses leading to increased inflammation and 
tumorigenesis in exGF mice. Alternatively, Dehalobacteriaceae, Peptococcaceae, and 
Ruminococcaceae, which have been linked to protection from CAC (24-26), were significantly 
reduced in exGF mice. These findings provide insight into how the altered microbiota in exGF 
mice may lead to enhanced CAC.     
Collectively, our results suggest that CAC susceptibility in adulthood may be imprinted 
in the prenatal and/or early postnatal period by maternal-derived microbiota (27). Additional 
insights into how early-life exposure to microbiota regulates intestinal homeostasis, 
inflammation, and tumorigenesis may lead to opportunities for targeted interventions (28,29).   
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Figure Legends 
 
Figure 1. Absence of microbiota prior to weaning exacerbates CAC in adult mice. A, 
Experimental flow chart. SPF mice (n=15; 8 male and 7 female) and exGF mice (n=13; 7 male 
and 6 female) were injected intraperitoneally with AOM (10mg/kg body weight) at day 42 of life 
followed by two 7-day cycles of 2.5% DSS in the drinking water. Mice were euthanized at day 
122 of life. B, Body weight of SPF and exGF mice treated with AOM/DSS. C. (DSSx1; 1
st
 cycle 
of DSS; DSSx2 2
nd
 cycle of DSS) Representative colonoscopy from each group at day 98 and 
122. D, Representative images of the distal colon at day 122. E-F, Total number of tumors and 
tumor surface areas in the colon at day 122. G, Tumor number and size were measured under a 
dissecting microscope. H, Spleen weight and colon length from each group. Student’s t test was 
used to determine significance. Data are the means ± SEM. **P < 0.01, ***P < 0.001; NS, not 
significant. 
 
Figure 2. ExGF mice exhibit altered microbiota composition and intestinal gene expression. 
A, Microbiota composition was analyzed by 16S rRNA sequencing at day 42. PCoA of the 
unweighted Unifrac distance, with samples colored by group (SPF: blue, n=9 and exGF: red, 
n=7). ANOSIM P < 0.01. B, Unweighted Unifrac distance within and between SPF and exGF 
groups at day 42 (red), day 98 (blue), and day 122 (orange). Data are means ± SEM. *P < 0.05, 
***P < 0.01. C, LEfSe analysis investigating the bacterial taxa significantly increased (green) or 
decreased (red) in exGF mice compared to SPF mice. D, RNA-seq data were visualized on a 
volcano plot comparing gene expression in SPF and exGF mice. For each gene, the difference in 
abundance between the two groups is indicated in log2 fold-change on the x-axis, with positive 
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values corresponding to increased expression in exGF mice compared to SPF mice and negative 
values corresponding to decreased expression in exGF mice compared to SPF mice. Significance 
between the two groups is indicated by –log10 P-value on the y-axis. Red dots correspond to 
genes with a P-value <0.05 between exGF and SPF mice. Blue dots correspond to genes with at 
least a 2-fold decreased or increased expression in exGF and SPF mice. Green dots correspond to 
genes with at least a 2-fold decreased or increased abundance in exGF and SPF mice and a P-
value <0.05. One-way ANOVA and Bonferroni post-hoc test was used to determine significance. 
Data are from (C,D) one or (A,B) two independent experiments.  
 
Figure 3. CXCR2 ligands and G-MDSCs are enhanced in colons of AOM/DSS-treated 
exGF mice. A, The mRNA expression of CXCL1, CXCL2, and CXCL5 in colonic tumor (T) 
and matched non-tumor (N) mucosa were determined by qPCR at day 122. Black and red bars 
represent the samples from SPF mice and exGF mice, respectively. B-E, Infiltration of MDSC 
subsets into the colons in exGF mice in response to AOM/DSS. B,D, Lamina propria cells were 
isolated from colonic tissue and the frequencies of MDSCs in SPF (n=12; 6 males and 6 females) 
and exGF mice (n=11; 6 males and 5 females) were analyzed using flow cytometry by staining 
for Ly6G, Ly6C, CD11b. C,E, Each dot represents the frequency of the indicated MDSC 
subpopulation in the colonic mucosa for an individual mouse. One-way ANOVA and Tukey’s 
Multiple Comparison Test was used to determine significance. Data are from two independent 
experiments showing the means ± SEM. *P < 0.05, **P < 0.01; NS, not significant. 
 
Figure 4. Blockade of CXCR2 ameliorates carcinogenesis in exGF mice. A, Gross view of 
colonic tumors in AOM/DSS-treated SPF (n=16; 8 males and 8 females) and exGF mice (n=15; 
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8 males and 7 females) injected with control antibody (IgG) or a CXCR2 neutralizing antibody 
(500 g twice a week; SPF/cont IgG, n=8; SPF/aCXCR2, n=8; exGF/cont IgG, n-8; 
exGF/aCXCR2, n=7). B, Total tumor surface area and C, tumor surface area per tumor in the 
colon at day 80 after initiation of the AOM/DSS regimen (day 122 of life). D, total tumor 
number was quantified using a dissecting microscope. E, Spleen weight and colon length from 
each experimental group were determined. F, Each dot represents the frequency of the indicated 
MDSC subpopulation (G-MDSC: CD11b
+
Ly6G
high
; M-MDSC: CD11b
+
Ly6C
high
) in the colonic 
mucosa from individual mice in the indicated groups. One-way ANOVA and Tukey’s Multiple 
Comparison Test was used to determine significance. Data are from one experiment showing the 
means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant.  
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